COMBIDEX ® (ferumoxtran-10) Introduction, Combidex, Indication Mark Roessel Vice President Regulatory Affairs, Advanced Magnetics, Inc. Yoshimi Anzai, MD Associate Professor of Radiology, University of Washington
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Vice President Regulatory Affairs,
Advanced Magnetics, Inc.
Yoshimi Anzai, MDAssociate Professor of Radiology, University of Washington
Michael Bettmann, MDProfessor & Vice Chair for Interventional Services, Wake Forest University School of Medicine – Radiology
Steven Harms, MDDepartment of Radiology, University of Arkansas
Richard Wahl, MDProfessor of Radiology & Oncology, Johns Hopkins Hospital
Dror Michaelson, MD, PhDAssistant of Medicine, Massachusetts General HospitalConsultants
Combidex® (ferumoxtran-10) is for intravenous administration as a contrast agent for use with magnetic resonance imaging (MRI). Combidex can assist in the differentiation of metastatic and non-metastatic lymph nodes in patients with confirmed primary cancer who are at risk for lymph node metastases.
The information provided by Combidex should be considered in conjunction with other diagnostic information and lymph node findings from Combidex images should be pathologically confirmed unless medically contraindicated.Indication